HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Afterload reduction by hydralazine in children with a ventricular septal defect as determined by aortic input impedance.

Abstract
Hydralazine was administered at cardiac catheterization to eight children with a ventricular septal defect (age: 2.2-8.8 years), and the extent of afterload reduction was determined using aortic input impedance and wall stress. The pulmonary to systemic blood flow ratio decreased from 2.2 +/- 0.8 to 1.8 +/- 0.4 (p < 0.05) and the pulmonary systemic resistance ratio increased from 0.11 +/- 0.08 to 0.13 +/- 0.10 (p < 0.05) after hydralazine administration. Hydralazine reduced mean aortic pressure and the amplitude of the late systolic peak of the aortic pressure wave. Peak flow velocity in the descending aorta increased from 62 +/- 14 to 81 +/- 24 cm/sec (p < 0.05). Peripheral resistance decreased significantly from 13.3 +/- 5.9 to 6.6 +/- 3.7 10(3) dyn sec/cm3 (p < 0.05). The modulus of the first harmonic, indicating pulse wave reflection, decreased from 1196 +/- 575 to 815 +/- 382 dyn sec/cm3 (p < 0.05). The characteristic impedance, indicating aortic stiffness, did not change. End-systolic wall stress decreased significantly from 54.4 +/- 16.7 to 34.8 +/- 10.2 g/cm2 (p < 0.01). Hydralazine acutely achieved afterload reduction by reducing both peripheral resistance and pulse wave reflection, and increased stroke volume.
AuthorsH Endo, H Shiraishi, M Yanagisawa
JournalCardiovascular drugs and therapy (Cardiovasc Drugs Ther) Vol. 8 Issue 1 Pg. 161-6 (Feb 1994) ISSN: 0920-3206 [Print] United States
PMID8086327 (Publication Type: Journal Article)
Chemical References
  • Hydralazine
Topics
  • Aorta (drug effects, physiopathology)
  • Cardiac Catheterization
  • Child
  • Child, Preschool
  • Electric Impedance
  • Female
  • Heart Septal Defects, Ventricular (drug therapy, physiopathology)
  • Hemodynamics (drug effects)
  • Humans
  • Hydralazine (pharmacology, therapeutic use)
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: